- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| GENFLEET THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.12.25 | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT FIRST SITE INITIATED IN A REGISTRATIONAL STUDY OF GFH375 FOR METASTATIC PANCREATIC CANCER, AS FIRST-IN-WORLD ... | 1 | HKEx | ||
| 24.11.25 | GENFLEET-B (02595): PROPOSED ADOPTION OF THE H SHARE OPTION SCHEME AND THE H SHARE INCENTIVE SCHEME | 1 | HKEx | ||
| 22.10.25 | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN A PHASE IB/II STUDY OF GFH375, AN ORAL KRAS G12D (ON/OFF) INHIBITOR, COMBINED WITH CETUXIMAB ... | 2 | HKEx | ||
| 21.10.25 | Verastem stock falls after GenFleet's PDAC study shows lower efficacy data | 1 | Investing.com | ||
| 21.10.25 | GENFLEET-B (02595): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 21.10.25 | GENFLEET-B (02595): AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx | ||
| 21.10.25 | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 20.10.25 | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT EFFICACY DATA OF GFH375, AN ORAL KRAS G12D (ON/OFF) INHIBITOR, FOR PANCREATIC DUCTAL ADENOCARCINOMA PATIENTS ... | 1 | HKEx | ||
| 19.10.25 | Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma | 556 | Business Wire | GFH375 resulted in a 41% ORR for patients with heavily pre-treated pancreatic ductal adenocarcinoma (68% had received 2 or more prior lines of therapy) at the 600 mg daily dose At month four... ► Artikel lesen | |
| 16.10.25 | GENFLEET-B (02595): FULL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD | - | HKEx | ||
| 15.10.25 | GENFLEET-B (02595): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
| 15.10.25 | GENFLEET-B (02595): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx | ||
| 30.09.25 | GENFLEET-B (02595): 2025 INTERIM REPORT | 1 | HKEx | ||
| 29.09.25 | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED WITH GFH276, A MOLECULAR GLUE PAN RAS (ON) INHIBITOR, IN A PHASE I/II STUDY TREATING RAS-MUTANT ... | - | HKEx | ||
| 19.09.25 | GENFLEET-B (02595): DATE OF BOARD RESOLUTIONS AND DATE OF PUBLICATION OF INTERIM REPORT | 1 | HKEx | ||
| 19.09.25 | BRIEF: GenFleet shares double in heavily oversubscribed IPO | 1 | Bamboo Works | ||
| 18.09.25 | GENFLEET-B (02595): ANNOUNCEMENT OF ALLOTMENT RESULTS | 3 | HKEx | ||
| 18.09.25 | GENFLEET-B (02595): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 18.09.25 | GENFLEET-B (02595): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 18.09.25 | GENFLEET-B (02595): TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|
GENFLEET THERAPEUTICS SHANGHAI INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLEET THERAPEUTICS SHANGHAI INC finden Sie auf Wallstreet Online.